Rafael Rivera
Interventional Cardiology · Ponce, PRNPI 1003911264
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 407 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.
Across 407 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Johnson & Johnson$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Abbott$1K
- Edwards Lifesciences$903
- AstraZeneca$693
- plus $3K from 16 others
What the payments were for
- Travel & lodging$3753%
- Food & beverage$10,26896%
- Education$30%
- Gifts$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 60 | $2,076 |
| Johnson & Johnson | 69 | $1,479 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 63 | $1,245 |
| Abbott | 39 | $1,058 |
| Edwards Lifesciences | 26 | $903 |
| AstraZeneca | 30 | $693 |
| Amgen | 12 | $640 |
| PBG Puerto Rico LLC | 36 | $625 |
| Boston Scientific | 22 | $480 |
| Boehringer Ingelheim | 8 | $340 |
| Novartis | 14 | $322 |
| E.r. Squibb & Sons, L.L.C. | 5 | $214 |
| Merck | 6 | $182 |
| Bayer | 2 | $132 |
| Chiesi USA, Inc. | 2 | $93 |
| Teleflex LLC | 2 | $72 |
| Cordis US CORP. | 4 | $62 |
| Bayer Puerto Rico Inc. | 2 | $43 |
| Pfizer Pharmaceuticals LLC | 2 | $32 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Cardinal Health P.r. 120 Inc | 1 | $11 |
| Pfizer | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,721 in reported general payments places this provider in the 45th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 208 | $149,147 |
| EliquisApixaban | 184 | $131,661 |
| BrilintaTicagrelor | 167 | $92,130 |
| JardianceEmpagliflozin | 82 | $66,360 |
| EntrestoSacubitril/Valsartan | 70 | $54,768 |
| FarxigaDapagliflozin Propanediol | 64 | $40,022 |
| Repatha SureclickEvolocumab | 45 | $25,523 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 169 | $16,030 |
| Metoprolol Succinate | 1,128 | $12,482 |
| Atorvastatin Calcium | 1,098 | $9,939 |
| Repatha SyringeEvolocumab | 20 | $9,188 |
| Candesartan Cilexetil | 135 | $8,773 |
| Nifedipine ErNifedipine | 231 | $4,700 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 319 | $4,485 |
| Losartan Potassium | 506 | $4,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,479 | $149,147208 claims |
| AstraZenecaBrilinta, Farxiga | $693 | $132,151231 claims |
| PfizerEliquis | $3 | $131,661184 claims |
| Boehringer IngelheimJardiance | $340 | $66,36082 claims |
| NovartisEntresto | $322 | $54,76870 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Ponce
- Alejandro Lopez MasPonce$142K
- Enrique Hernandez VilaPonce$44K
- Cesar Cruz GarciaPonce$14K
- Jorge Jovane JaramilloPonce$3K
- Emilio del Toro AgrelotPonce$708
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Ricardo SantiagoManati$131K
- Edwin I Perez MarreroSan Juan$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.